AGC Acquires Biopharmaceutical Commercial Facility in Colorado, U.S.A.
AGC a world-leading manufacturer of glass, chemicals and high-tech materials,
announced the purchase of a biopharmaceutical commercial manufacturing facility in Boulder, Colorado, USA.
The facility, formerly owned by AstreaZeneca, will provide AGC with additional capacity and significantly larger production scale.
AGC will prepare for the plant to resume full-scale operations by April 2021.
AGC Biologics (Headquarters: U.S.A.),
a CDMO1 subsidiary of the company,
utilizes mammalian cells and microorganisms to provide a variety of high value-added services that range from process development to scale-up, and manufacturing of biopharmaceutical APIs.
The Colorado facility
is a large-scale biopharmaceutical manufacturing plant that houses two 20,000-liter (total volume) stainless steel mammalian cell bioreactors, and is well suited for higher volume commercial production.
News ｜ AGC